Randomized Controlled Trial Comparing Primary and Staged Basilic Vein Transposition by Stavros K. Kakkos et al.
CLINICAL TRIAL
published: 29 April 2015
doi: 10.3389/fsurg.2015.00014
Edited by:
Mounir J. Haurani,
The Ohio State University, USA
Reviewed by:
Randall William Franz,
OhioHealth, USA
Mojahid Najem,
Edinburgh University, UK
*Correspondence:
Stavros K. Kakkos,
Department of Vascular Surgery,
University of Patras Medical School,
Patras 26504, Greece
kakkos@upatras.gr
Specialty section:
This article was submitted to Vascular
Surgery, a section of the journal
Frontiers in Surgery
Received: 18 March 2015
Accepted: 09 April 2015
Published: 29 April 2015
Citation:
Kakkos SK, Tsolakis IA, Papadoulas
SI, Lampropoulos GC, Papachristou
EE, Christeas NC, Goumenos D and
Lazarides MK (2015) Randomized
controlled trial comparing primary and
staged basilic vein transposition.
Front. Surg. 2:14.
doi: 10.3389/fsurg.2015.00014
Randomized controlled trial
comparing primary and staged
basilic vein transposition
Stavros K. Kakkos 1*, Ioannis A. Tsolakis 1, Spyros I. Papadoulas 1,
George C. Lampropoulos 1, Evangelos E. Papachristou 2, Nikolaos C. Christeas 3,
Dimitrios Goumenos 2 and Miltos K. Lazarides 4
1 Department of Vascular Surgery, University Hospital of Patras, Patras, Greece, 2 Department of Nephrology, University
Hospital of Patras, Patras, Greece, 3 Department of Interventional Radiology, University Hospital of Patras, Patras,
Greece, 4 Department of Vascular Surgery, Democritus University Hospital, Alexandroupolis, Greece
Objective: It is unclear if brachio-basilic vein fistula should be performed as a primary
or staged procedure, particularly for smaller basilic veins. Our aim was to report on a
randomized controlled trial comparing these two techniques.
Methods: Sixteen patients with a basilic vein 2.5mm were randomized into primary
transposed brachio-basilic vein (TBBV) fistula (n=9) and staged TBBV fistula (n=7).
Patients with basilic veins enlarged by previous arteriovenous fistulas were excluded.
Baseline characteristics of the two study groups, including vein size, were compara-
ble (median basilic vein diameter 3.5mm, range 2.8–4.1mm). The staged group had
a brachio-basilic vein fistula performed first followed by the transposition procedure
performed at least 6weeks later to allow the basilic vein to enlarge. TBBV fistula
maturation at 10weeks, primary, assisted-primary, and secondary patency were the
primary outcome measures. Early failures were included in the calculation of patency
rates.
Results: Transposed brachio-basilic vein fistula maturation rate after primary procedures
(3/9, 33%) was lower compared to maturation rate after staged procedures (7/7, 100%,
P=0.011, Fisher’s exact test), which led to premature termination of the trial. Time to
hemodialysis [median (interquartile range)] of primary and staged procedures was 54
(51.5–113.5) days and 97 (93–126) days, respectively (P=0.16). One-year primary and
assisted-primary patency rates of primary and staged procedures were equivalent (44
vs 57%, P=0.76 and 44 vs 71%, P=0.29, respectively); however, there was a trend
toward a better 1-year secondary patency after staged procedures (86 vs 44% for primary
procedures, P=0.09).
Conclusions: Among candidates for TBBV fistula with a small basilic vein, staged
transposition achieves higher maturation rates compared to primary procedures, a
difference reflected in long-term secondary patency.
Trial registration: www.ClinicalTrials.gov, identifier NCT01274117.
Keywords: arteriovenous recommend that fistula, basilic vein, transposition, maturation, patency
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Introduction
Current guidelines recommend that transposed brachio-basilic
vein (TBBV) fistulae (1) should be preferred over prosthetic grafts
in patients with unsuitable cephalic veins or exhausted cephalic
vein options (2), because they have better primary patency and
lower infection rates and are associatedwith better patient survival
when compared with prosthetic grafts.
The original technique of TBBV fistula was a primary basilic
vein transposition, i.e., a one-stage procedure (1). More recently,
staging of TBBV fistula was suggested (3), with the arteriovenous
anastomosis performed during the first stage and the formal
transposition performed after a period of several weeks. Inter-
val arterialization makes staged transposition easier, because the
basilic vein is enlarged and its walls are thickened and not small
and friable, and perhaps faster than primary transpositions. Addi-
tionally, a small and thin-walled basilic vein can be twisted or
compressed by a hematoma in the transposition tunnel or can
be short, requiring a more proximal anastomosis. In case steal
syndrome or venous hypertension develops after a primary TBBV
fistula, an extensive and complex operation has been performed
with no benefit. In staged procedures, these complications can
be managed before the transposition is performed. The obvious
disadvantage of procedure staging is the additional delay in TBBV
fistula use.
There is some supportive evidence in favor of staged TBBV
fistula from a single-center study, which found improved matu-
ration rates with procedure staging compared with the primary
technique (4). However, this study was performed in the early
1990s when preoperative vessel mapping was not used, the ran-
domization method that was used was not reported and the
exclusion criteria were not provided. At present, it remains unclear
if TBBV fistula should be performed as a primary (one-stage) or
staged (two-stage) procedure, particularly in smaller basilic veins.
The equivalent results of case–control studies (5, 6), suggest that
staging might not be necessary; however, their findings could be
the result of bias, because staged procedures are usually performed
in patients with basilic veins of smaller diameter.
The aim of the present study was to report on a ran-
domized controlled trial (RCT, ClinicalTrials.gov identifier,
NCT01274117) comparing the short- and long-term results of
primary and staged TBBV fistula.
Materials and Methods
Suitable patients with chronic kidney disease (CKD) were ran-
domized to have a TBBV fistula performed either as a primary or a
staged procedure (randomization ratio 1:1). The protocol appears
on www.clinicaltrials.gov (identifier NCT01274117).
Inclusion and Exclusion Criteria
Patients between 18 and 90 years of age of both genders, with CKD
already on hemodialysis or with anticipated hemodialysis were
eligible for inclusion. Patients were excluded if they were unwill-
ing to participate and/or not consenting, had a suitable cephalic
vein to construct a radio-cephalic or brachio-cephalic fistula, the
basilic vein was unsuitable for use because it measured less than
2.5mmor had intrinsic lesions on color-codedDuplex ultrasound
(CCDU), or the basilic vein was already enlarged by a previous
wrist or elbow arteriovenous fistula draining into the basilic vein
on CCDU, as detailed below. Preoperative vessel mapping was
performed with CCDU and selective use of venography (7), with
the minimum and maximum diameter of the basilic vein being
recorded, after application of a tourniquet, including the diam-
eter of the medial antecubital (basilic) vein. Particular attention
was made to identify drainage patterns of previous AVFs (radio-
cephalic and brachio-median cubital) leading to enlargement of
the basilic vein in order to exclude these patients from the trial
and also to completely map the basilic vein in order to choose the
incision site (8).
Patients were recruited from the Vascular Access Outpatient
Clinic of the University Hospital of Patras, Greece, and enrolled
during the period between December 2010 and April 2013. The
study protocol was approved by the Ethics Committee of the Uni-
versityHospital of Patras, Greece; all participants providedwritten
informed consent and the trial conformed to the Declaration of
Helsinki.
Surgical Techniques
All procedures were performed by the first author using mag-
nifying loupes (2.5) under local anesthesia with lidocaine 1%
(Xylocaine, AstraZeneka, Södertälje, Sweden), preferentially on
an outpatient setting. Heparinization was performed with 2,500 iu
of heparin sodium in the form of basilic vein flush.
Primary procedures (1, 5, 9) were performed with the modifi-
cation of skip incisions to dissect the basilic vein. A large subcuta-
neous tunnel was created (10), and a 7-mm brachial arteriotomy
was used. The staged group had a brachio-basilic vein (BBV)
fistula performed first, through a transverse antecubital incision
approximately 1 cm distal to the elbow crease using the same
arteriotomy length (7mm) as in primary procedures. Whenever
the median antebrachial vein was not suitable, the main basilic
vein was used to create the anastomosis through a longitudinal
incision. The transposition procedure was performed at least
6 weeks later to allow the basilic vein to enlarge, guided by an
interval CCDU to confirm this (desirable vein diameter6mm),
using skip incisions, basilic vein transection, placement into the
tunnel, and reanastomosis (5). Previously described modified
techniques of basilic vein transposition, guided by the preoper-
ative CCDU and operative findings were selectively used when
indicated (11–13).
Outcome Measures
Primary outcomes included TBBV fistula maturation defined
as usage of the fistula for three consecutive sessions with two
needles (or clearance for use in case of pre-dialysis) between 6
and 10weeks after the transposition procedure (main primary
outcome measure subject to power calculations), and long-term
primary, primary assisted, and secondary patency.
Reporting standards for arteriovenous accesses of the Society
for Vascular Surgery and the American Association for Vascu-
lar Surgery were used to define access patency (14). Primary
patency was defined as fully functional access, the first episode
of failure or thrombosis being used to determine this outcome.
Assisted-primary patency was defined as patent access without
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thrombectomy, including those in which any intervention had
been performed to prevent what was perceived to be impending
failure, so that patency is lost when the first thrombosis occurred.
Secondary patency was defined as accesses that were patent after
thrombectomy, the terminal thrombotic event being taken into
account to estimate secondary access patency rates.
Secondary outcome measures included basilic vein diameter
on ultrasound at 4weeks after the procedure, overall maturation
(irrespective of time required to achieve this), postoperative and
long-term complications (including hematoma, steal syndrome,
and venous hypertension), and full time to usage of the TBBF fis-
tula (or clearance in case of pre-dialysis) after the initial procedure.
Sample Size Determination
Based on the results of a similar study (4), where maturation
rates of 90% for staged procedures and 60% for primary proce-
dures were reported, it was estimated that 20 patients in each
group would be required for the main primary outcome measure,
maturation (α= 0.05, β= 0.10). A formal interim analysis was
not planned; however, maturation results were closely monitored
because of the open-label design of this surgical trial.
Randomization
All patients provided written informed consent before entering
the study. Randomization was performed using sequentially num-
bered sealed opaque envelopes, stratified by vein size (2.5–3.9mm
and 4mm, based on previously suggested empirical evidence)
(8). To avoid crossover of patients and minimize the possibility
of consent withdrawal, the envelopes were opened up at the time
of surgery, before the incision was made. Obviously, blinding
was not possible for this trial on surgical procedures; however,
with the course of time, the antecubital fossa scar tended to fade-
away reducing detection bias, which was nevertheless based on
objective hard endpoints of maturation and patency.
Statistics
All data of our RCT were entered into a Microsoft Office Access
database (Microsoft Inc., Redmond,WA, USA) and analyzed with
IBM SPSS Statistics 21 (IBMCorp., Armonk, NY, USA). All access
patency rates were calculated with the Kaplan–Meier method and
compared with the log-rank (Mantel–Cox) test. Patients were
followed-up for a minimum of 1 year and up to the point sec-
ondary patency was lost, while initial failures were included in the
calculation of long-term patency rates. Categorical data were ana-
lyzed with the chi-square or Fisher’s exact test, where appropriate;
numerical datawere analyzedwith theMann–Whitney test, where
appropriate. Relative risk for non-thrombotic complications was
calculated, but this was not estimable for maturation because of
the absence of events in the staged TTBV fistula group. Similarly,
relative risks for long-term patency results were calculated using
Cox proportional hazards modeling. A P-value <0.05 was con-
sidered as statistically significant. Two-sided statistical tests were
always used.
Results
Forty patients were assessed for eligibility, with 24 of them being
excluded as shown in Figure 1. Of those excluded, 13 patients
did not meet the inclusion criteria and were not randomized: six
patients had enlarged basilic veins – median diameter 7.1mm
and range 4.5–9.2mm – from previous fistulas and underwent
a primary TBBV fistula; seven patients had anatomical reasons,
including small basilic vein in five of them, small brachial artery
in one of them, and extensive scarring at the elbow due to pre-
vious brachio-cephalic fistula, all but one undergoing placement
of a prosthetic graft; one patient refused to participate and an
additional 10 patients were excluded, per investigators’ choice to
receive a loop forearm graft (n= 2) at the beginning of our series
or an upper arm graft (n= 7), or for other reasons (n= 1).
The remaining 16 patients were randomized into primary
TBBV fistula (n= 9) and staged TBBV fistula (n= 7). Base-
line characteristics (demographics, pertinent history and co-
morbidities) of the two study groups are demonstrated in Table 1
and were comparable; however, a marginally significant differ-
ence for antithrombotic treatment being used more frequently
in two-staged procedures was noted. Only four patients had a
basilic vein of 4mm or larger and three of them were randomized
to primary TBBV fistula. Similarly, preoperative vessel mapping
results, including minimum basilic vein size, were comparable
(Table 2). The median minimum basilic vein diameter of both
groups was 3.5mm (range 2.8–4.1mm). A relevant finding in
primary procedureswas one case of a duplicated basilic vein, while
in four patients of staged procedures, there were quality issues
of the medial basilic vein (n= 3) or scarring due to a previous
brachio-cephalic fistula (n= 1) requiring the main basilic vein to
be anastomosed to the brachial artery (or the radial artery in a
patient with a known high bifurcation) at the level or just above
the elbow crease.
Basilic veins were equally enlarged 1month after the TBBV fis-
tula (primary procedures) or the BBV fistula (staged procedures),
with median minimum fistula diameter being 5.9 vs 4.6mm,
respectively, P= 0.09 (Table 2). The median (interquartile range)
interval between the stages of the staged group was 55 (47–76)
days. In four of the patients undergoing the second stage of the
staged procedure, a technical modification was required in the
form of concomitant brachial vein harvesting (because of a low
basilic vein junction), relocation of the brachial anastomosis above
the elbow crease (because of small – 3mm – diameter of the
proximal basilic vein, apparently a failure to enlarge), resection
of a proximal fibrotic/stenotic part and creation of the anastomo-
sis with the two fistula stumps, and division of the basilic vein
near the axilla and reanastomosis (because of a 5mm/partially
enlarged proximal basilic vein, likely to fail or become stenotic if
anastomosis was to be made at this level). One more patient with
a duplicated basilic vein underwent transposition of both ramii,
each measuring at least 6mm in diameter.
TBBF fistula maturation by week 10 with staged operations
(7/7, 100%) was significantly better compared to primary oper-
ations (3/9, 33%, P= 0.011, Fisher’s exact test), but also final mat-
uration rate with staged operations (7/7, 100%) was significantly
better compared to primary operations (4/9, 44%, P= 0.034,
Fisher’s exact test), which led to premature termination of the trial.
More specifically, one TBBV fistula was found thrombosed by
the 1-month follow-up, a second one was thrombosed while the
patient was awaiting repair of an anastomotic pseudoaneurysm
Frontiers in Surgery | www.frontiersin.org April 2015 | Volume 2 | Article 143
Kakkos et al. RCT of basilic vein transposition
Assessed for eligibility (n=40)
Excluded (n=24)
♦ Not meeting inclusion criteria (n=13)
♦ Declined to participate (n=1)
♦ Other reasons (n=10)
Analysed (n=9)
Lost to follow-up (give reasons) (n=0)
Allocated to one-stage transposition (n=9)
♦ Received allocated intervention (n=9)
Lost to follow-up (give reasons) (n=0)
Allocated to two-stage transposition (n=7)
♦ Received allocated intervention (n=7)
Analysed (n=7)
Allocation
Analysis
Follow-Up
Randomized (n=16)
Enrollment
FIGURE 1 | Consolidated Standards of Reporting Trials (CONSORT) Statement 2010 flow diagram showing the enrollment, allocation, follow-up, and
analysis stages of our RCT.
(see below), a third one was abandoned due to low flows and
soon was thrombosed, a fourth one thrombosed during the sec-
ond postoperative month before it was deemed mature, and the
fifth one was thrombosed before fully used (one needle trial)
possibly in relation to prolonged bleeding requiring application
of local pressure. The single patient on pre-dialysis started using
his TBBV fistula 1 year after it was released for use. There was
no association between TBBF fistula maturation by week 10 and
final maturation rates and use of antithrombotics (P= 0.25 and
P= 0.51, respectively).
Time to hemodialysis was longer after staged procedures com-
pared to primary procedures (Table 3). Non-thrombotic post-
operative and TBBV fistula-related complications after primary
and staged procedures occurred in 5/9 (56%) and 3/7 (43%)
patients, respectively (P= 1.00, Fisher’s exact test, Table 2, RR
1.29, 95% CI 0.49–3.40). In the primary TBBV fistula group, these
complications included extensive arm bruising and hematoma
(requiring hospitalizationmost likely due to an anastomotic pseu-
doaneurysm diagnosed at 30 days) in two patients, respectively,
a puncture-related pseudoaneurysm (requiring operative repair)
in a third patient, prolonged bleeding in a forth patient and re-
circulation due to the short length of the available basilic vein
(requiring complementary transposition) in the fifth patient. In
the staged group, these complications included grade 1 steal
syndrome (after the BB fistula, spontaneously resolved), grade 1
venous hypertension (after the transposition procedure, managed
conservatively) and wound infection with dehiscence after both
procedure stages, requiring debridement of the axillary wound
and healing by third intention after the transposition in a patient
with SLE on corticosteroids.
One-year primary and assisted-primary patency rates of pri-
mary and staged procedures were equivalent (44 vs 57%, P= 0.76,
Figure 2A, and 44 vs 71%, P= 0.29, Figure 2B, respectively).
There was amajor trend toward a better 1-year secondary patency
after staged procedures compared to primary procedures (86 vs
44%, respectively, P= 0.09, Figure 2C); however, after the initial
failures of primary procedures, the two techniques seem to per-
form equally well (Figure 2C). Repeat analysis excluding initial
failures showed a trend for better 1-year primary patency rates of
primary procedures (100 vs 57%, for staged procedures, P= 0.08);
however, 1-year assisted-primary and secondary patency rates
of primary and staged procedures were equivalent (100 vs 71%,
P= 0.27, and 100 vs 86%, P= 0.45, respectively). No patient was
lost to follow-up. Minimum and maximum follow-up was 1 and
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TABLE 1 | Demographics, pertinent history and co-morbidities of patients
randomized into the two study groups, primary and staged TBBV fistula.
TBBV fistula P value All patients
Primary
(n=9)
Staged
(n=7)
Age [median, (IQR), years] 61 (53.5–71) 59 (43–67) 0.68 60.5
(50.5–67.0)
Gender (male/female) 3/6 4/3 0.62 7/9
Race (caucasian/other) 9/0 6/1 0.44 15/1
Pre-dialysis (%) 0 (0%) 1 (14.3%) 0.44 1 (6.3%)
Chronic kidney disease
cause (%)
Diabetes mellitus 2 (22.2%) 0 (0%) 0.32 2 (12.5%)
Hypertension 1 (11.1%) 1 (14.3%) 2 (12.5%)
Glomerulonephritis 3 (33.3%) 3 (42.9%) 6 (37.5%)
Interstitial disease 1 (11.1%) 1 (14.3%) 2 (12.5%)
Cystic disease 0 (0%) 2 (28.6%) 2 (12.5%)
Unknown 2 (22.2%) 0 (0%) 2 (12.5%)
History of previous
ipsilateral access (%)
4 (44%) 4 (57%) 1.00 8 (50%)
Radio-cephalic AVF 2 (22%)a 3 (43%)b 0.60 5 (31.3%)
Brachio-cephalic AVF 2 (22%)b 1 (14%)b 1.00 3 (18.8%)
Co-morbidities 7 (78%) 7 (100%) 0.48 14 (87.5%)
Diabetes mellitus 1 (11%) 2 (28%) 0.55 3 (18.8%)
Hypertension 3 (33%) 4 (57%) 0.62 7 (43.8%)
Other 6 (67%) 6 (86%) 0.59 12 (75%)
Antithrombotic treatment 0 (0%) 3 (43%)c 0.06 3 (18.8%)
AVF, arteriovenous fistula.
aAll failed to mature.
bOne AVF failed to mature, two AVFs used for 18 and 24months, respectively.
cTwo patients on antiplatelets and one on anticoagulation with acenocoumarol.
3 years, respectively. All patients were alive at the end of the study
except onewith awell-functioning primaryTBBV fistulawhodied
23months postoperatively due to sepsis after heart surgery.
Discussion
We have demonstrated that TBBF fistula maturation with staged
operations is significantly better than primary procedures. Pri-
mary and assisted-primary patency of the two techniques is equiv-
alent; however, there is a trend toward a better 1-year secondary
patency after staged procedures, as a result of the worse perfor-
mance of primary transposition.
The present RCT has demonstrated that maturation rates after
primary procedures are significantly worse than those of staged
procedures. In the absence of previous arterialization, the basilic
vein can be very thin-walled and friable, susceptible to damage
in primary procedures. Also, the basilic vein may be twisted or
compressed by hematoma in the tunnel more often in primary
procedures than in staged procedures (15). Our results, were not
only expected but also in agreement with one of the two RCTs
on this topic, which reported maturation rates of 90% with staged
procedures vs 60% with primary procedures (4), raising the level
of evidence (from level B to level A – two RCTs with consis-
tent results) (16). We attribute our somewhat worse maturation
rates with primary procedures to the fact that we randomized
only relatively small basilic veins and excluded those that were
TABLE 2 |Ultrasound findings and procedure details of patients randomized
into the two study groups, primary and staged TBBV fistula.
TBBV fistula P value
One-stage
(n=9)
Two-stage
(n=7)
Preoperative basilic vein diameter
[median, (IQR), mm]
Minimum 3.7 (3.2–4.0) 3.3 (3.2–3.4) 0.30
Maximum 5.5 (4.8–6.3) 5.1 (3.3–5.7) 0.41
Preoperative brachial artery diameter
[median, (IQR), mm]
4.5 (3.8–4.7) 4.5 (3.7–5.6) 0.76
TBBV fistula side (L/R) 6/3 3/4 0.62
Duration of first procedurea
[median, (IQR), min]
220 (163–270) 115 (75–120) <0.001
Postoperative complications of first
procedurea
5/9 (56%) 2/7 (29%) 0.36b
30-day basilic vein diameter
[median, (IQR), mm]
Minimum 5.9 (4.7–6.9) 4.6 (3.5–5.2) 0.09
Maximum 7.3 (6.2–7.8) 7.8 (6.7–8.5) 0.28
Time interval between stages in
2-stage procedures
[median, (IQR), min]
N/A 55 (47–76) N/A
Duration of transposition in 2-stage
procedures [median, (IQR), min]
N/A 180 (180–205) N/A
Postoperative complications of
transposition in 2-stage procedures
N/A 2/7 (29%) N/A
Postoperative complications (all
stages)
5/9 (56%) 3/7 (43%) 1.00c
aTBBV fistula and BB fistula, respectively.
bRelative risk 1.75, 95% CI 0.78–3.93.
cRelative risk 1.29, 95% CI 0.49–3.40.
arterialized based on history of proximal access and also findings
of CCDU scanning. The last modality was not reported to be
used in the above mentioned RCT (4), performed in the early
1990s before preoperative vesselmappingwas described leading to
improved results of AVF construction (17). On the other hand, the
second RCT failed to demonstrate a significant benefit with staged
procedures. Exclusion and inclusion criteria of the two studies
were not provided. In agreement with clinical experience, basilic
veins already enlarged by previousmore distal AVFs are associated
with good results regardless of staging or not the procedure, which
could explain the difference among the three trials in addition to
any bias.
In the present RCT, a delay to hemodialysis was inevitable for
patients randomized into staged procedures. Given the impor-
tance of achieving the goal of TBBV fistula maturation, it seems
obvious that with staged procedures the large outcome advan-
tage outweighs the relatively short inherent delay and its atten-
dant risks, taking into account a 10% 50-day infection rate of a
hemodialysis catheter (18), and a 10% 3-year infection rate of a
prosthetic graft (19), should such an option be opted. Delay to
hemodialysis, an obvious disadvantage of staged procedures (5),
was kept at a minimum in this RCT. Obviously, arterialized basilic
veins that are usually much larger do not need a staged procedure,
to avoid the risks of prolonged hemodialysis catheter use. To
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TABLE 3 | Dialysis-related outcomes of patients randomized into the two
study groups, primary and staged TBBV fistula.
TBBV fistula P value Relative risk
(95% CI)
One-stage
(n=9)
Two-stage
(n=7)
Time to hemodialysis
after the first procedure
[median, (IQR), days]a
54
(51.5–113.5)
97
(93–126)
0.16 –
Time to hemodialysis
after the transposition
procedure [median,
(IQR), days]
54
(51.5–113.5)
50
(38–58)
0.16 –
TBBV fistula
maturation by week 10
3/9 (33%) 7/7 (100%) 0.01 N/A
TBBV fistula
maturation
4/9 (44%) 7/7 (100%) 0.03 N/A
Primary patency 0.76 1.23
(0.33–4.61)
Year 1 44% 57%
Year 2 44% 43%
Assisted-primary
patency
0.29 3.38
(0.46–12.33)
Year 1 44% 71%
Year 2 44% 71%
Secondary patency 0.09 5.32
(0.62–45.76)
Year 1 44% 86%
Year 2 44% 86%
aTBBV fistula and BB fistula, respectively.
prevent this potential problem, others have suggested selective use
of staged procedures if the diameter of the basilic vein is smaller
than 4mm, a predictor for failure of maturation (8, 20). Of note,
two of the three TBBV fistulas that had a primary transposition
of a basilic vein diameter 4mm failed to mature; therefore, we
would suggest that for a non-enlarged basilic vein a cut-off point
of 5mm to be used. Further research could be performed to prove
this suggestion.
Long-term primary patency rates of the two study groups
are comparable, but our study was prematurely stopped before
the trend for secondary patency in favor of staged procedures
became significant. Better long-term results with staged proce-
dures compared to primary ones (RR 3.2) have been reported
in a case–control study although the maturation rates in the
two study groups were equivalent (6). Primary patency of the
two groups of our RCT is almost indistinguishable, indicative
that regardless of procedure staging, problems relating to stenotic
vein segments might arise during follow-up; however, if these
develop in primary transposition, they are usually irreversible
because of thrombosis of a small basilic vein that is placed inside
a hostile and actively remodeling subcutaneous tunnel, while in
staged procedures the basilic vein is already enlarged and less
likely to thrombose. Based on our RCT presented herein, it seems
that after the initial failures of primary procedures the two tech-
niques perform equally well, similarly to what has been shown
by another RCT (4). The very small number of interventions
FIGURE 2 | This figure shows the primary patency (A),
assisted-primary patency (B), and secondary patency (C) of the
patients randomized into primary and staged TBBV fistula. One-year
primary and assisted-primary patency rates of primary and staged procedures
were equivalent [44 vs 57%, P= 0.76, (A), and 44 vs 71%, P= 0.29,
(B), respectively]. There was a trend toward a better 1-year secondary
patency after staged procedures compared to primary procedures [86 vs
44%, respectively, P= 0.09, (C)].
that is necessary to maintain patency in our series, unlike pros-
thetic grafts, confirms the value of TBBV fistulas (9, 21). Post-
operative and long-term non-thrombotic complications, known
to occur frequently (22, 23), are in favor of staged TBBV fis-
tulas as previously described (5), although the difference is not
significant.
Meta-analyses comparing primary and staged BBV fistulas are
scarce. In such a study, which included mainly case-controlled
studies and only one RCT, there was a suggestion that the
two-stage technique was equally good with primary BBV fistulas
in terms of similar maturation and patency results (24).
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The limitations of our RCT include its small size; however,
its power is calculated to be 0.89 (two-sided test). An additional
limitation is the fact that the study was prematurely stopped and
as a result it could not detect any difference in long-term patency.
The large benefit with staged procedures in patients with small
and not arterialized veins precludes to our view any future trials;
obviously, patients with bigger and non-arterialized veins, rare
to recruit though, could be randomized into primary and staged
TBBV fistula, in view of the recently reported long-term patency
with the latter approach (6). Future work to our opinion should
also focus on techniques to improve further staged procedures
(11), including the direct comparison of superficialization with
formal transposition.
In conclusion, among candidates for TBBV fistula and small
basilic veins, our small study demonstrated that staged transpo-
sition is superior to primary procedures in terms of maturation,
a difference persisting in the long-term secondary patency of the
two groups.
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